Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SterisMEX:STE N 79 Piotroski F-Score is 8 as of Sep. 02, 2026, which is 14% above its 10-year median of 7.00. GuruFocus rates MEX:STE N with a GF Score™ of 79/100 and a GF Value™ of MXN4,746.25 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 814 Medical Devices & Instruments companies, Steris ranks better than 98.16% on this metric.
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Steris has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Steris's Piotroski F-Score or its related term are showing as below:
MEX:STE N'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 7 Max: 9
Current: 8
During the past 13 years, the highest Piotroski F-Score of Steris was 9. The lowest was 3. And the median was 7.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Steris Piotroski F-Score Related Terms
Steris Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Steris's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:STE N vs ZBH, GEHC, PEN: Piotroski F-Score Comparison
For the Medical Devices subindustry, Steris's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steris Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Steris's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Steris's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun26) TTM:
Last Year (Jun25) TTM:
Net Income was 3520.252 + 3471.499 + 3970.801 + 3491.545 = MXN14,454 Mil. Cash Flow from Operations was 5279.461 + 5369.3 + 6048.168 + 6405.528 = MXN23,102 Mil. Revenue was 26788.035 + 26940.128 + 28643.141 + 26046.122 = MXN108,417 Mil. Gross Profit was 11848.519 + 11802.736 + 12570.595 + 11938.606 = MXN48,160 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(195917.826 + 190975.963 + 190705.571 + 193620.707 + 187334.209) / 5 = MXN191710.8552 Mil. Total Assets at the begining of this year (Jun25) was MXN195,918 Mil. Long-Term Debt & Capital Lease Obligation was MXN30,806 Mil. Total Current Assets was MXN42,677 Mil. Total Current Liabilities was MXN22,392 Mil.
Net Income was 2955.514 + 3618.464 + 2980.76 + 3340.3 = MXN12,895 Mil.
Revenue was 26166.44 + 28582.737 + 30290.411 + 26193.3 = MXN111,233 Mil. Gross Profit was 11396.746 + 12728.234 + 13117.798 + 11824.738 = MXN49,068 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(185190.612 + 201670.908 + 208731.395 + 207585.264 + 195917.826) / 5 = MXN199819.201 Mil. Total Assets at the begining of last year (Jun24) was MXN185,191 Mil. Long-Term Debt & Capital Lease Obligation was MXN38,291 Mil. Total Current Assets was MXN38,747 Mil. Total Current Liabilities was MXN17,447 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Steris's current Net Income (TTM) was 14,454.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Steris's current ratio of this year was 1.90586765. Steris's current ratio of last year was 2.22080723.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Steris's number of shares in issue this year was 97.9. Steris's number of shares in issue last year was 98.8.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Steris's gross margin of this year was 0.44421324. Steris's gross margin of last year was 0.44112418.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Steris's asset turnover of this year was 0.55338214. Steris's asset turnover of last year was 0.60063999.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
0
+
1
+
1
+
0
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Steris has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Steris (MEX:STE N) has a Piotroski F-Score of 8 as of Sep. 02, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Steris and its competitors. This is 14% above median its historical median of 7.00. Over the past decade, Steris' Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Steris ranks #15 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 1.8%.
Is Steris' Piotroski F-Score too high?
Steris' current Piotroski F-Score of 8 is 14% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Steris' value of 8 is 60% above this industry median. Based on the distribution chart, Steris ranks #15 out of 814 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Steris has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Steris' Piotroski F-Score compare to ZBH and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Steris ranks #15 out of 814 companies for Piotroski F-Score. This places Steris in the top 2% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Steris' value of 8 is 60% above this benchmark. Historically, Steris' own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Steris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Steris's current Piotroski F-Score of 8 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Steris and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steris's current Piotroski F-Score is 8, which is 14% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Based on GuruFocus' analysis, Steris (MEX:STE N) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN4,746.25, compared to a current price of MXN4,038.00 — trading 14.9% below its estimated fair value. The current Piotroski F-Score is 8, which is 14% above median its 10-year median of 7.00 and 60% above the Medical Devices & Instruments industry median of 5.00. Steris' overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Steris (MEX:STE N), the current Piotroski F-Score is 8 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Steris (MEX:STE N) Overvalued in 2026?
Based on GuruFocus' analysis, Steris stock appears to be undervalued.
The current stock price of MXN4,038.00 is trading 14.9% below its estimated GF Value™ of MXN4,746.25.
GuruFocus considers Steris to be Modestly Undervalued.
Key valuation signals for MEX:STE N:
Piotroski F-Score: 8 (14% above median its 10-year median of 7.00)
GF Value™: MXN4,746.25 vs. price of MXN4,038.00 (14.9% below fair value)
Industry Position: 60% above the Medical Devices & Instruments median (#15 of 814)
No single metric tells the full story. See the MEX:STE N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
79GF Score
Get the complete analysis for MEX:STE N
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:STE N has been successfully added to your 
